<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Charcot-Marie-Tooth disease: Management and prognosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Charcot-Marie-Tooth disease: Management and prognosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Charcot-Marie-Tooth disease: Management and prognosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Peter B Kang, MD, FAAP, FAAN
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Douglas R Nordli, Jr, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Helen V Firth, DM, FRCP, FMedSci
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeremy M Shefner, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard P Goddeau, Jr, DO, FAHA
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 22, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1435550698">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Charcot-Marie-Tooth disease (CMT) consists of a spectrum of disorders caused by pathologic variants of various genes whose protein products are expressed in myelin and/or axonal structures within peripheral nerves.
        </p>
        <p>
         This topic will review the management and prognosis of CMT. Other aspects of CMT are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6220.html" rel="external">
          "Charcot-Marie-Tooth disease: Genetics, clinical features, and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2140447790">
         <span class="h1">
          BACKGROUND
         </span>
         <span class="headingEndMark">
          —
         </span>
         The genetics, clinical features, and diagnosis of CMT, summarized here briefly, are described in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/6220.html" rel="external">
          "Charcot-Marie-Tooth disease: Genetics, clinical features, and diagnosis"
         </a>
         .)
        </p>
        <p>
         CMT is genetically heterogeneous. The major categories of CMT are CMT types 1 through 7 as well as an X-linked category, CMTX. Within each category, a specific disease associated with a particular gene is assigned a letter (eg, CMT1A, CMT1B, etc). CMT1 (demyelinating) and CMT2 (axonal) represent by far the largest proportion of patients (
         <a class="graphic graphic_table graphicRef72688" href="/z/d/graphic/72688.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         The most common initial presentation of CMT is distal weakness and atrophy manifesting with foot drop and pes cavus. Sensory symptoms are often present but tend to be less prominent. Later in the course, foot deformities such as hammertoes ensue along with hand weakness and atrophy.
        </p>
        <p>
         A comprehensive history and physical examination remain the core of ascertainment of and evaluation for cases of CMT (see
         <a class="medical medical_review" href="/z/d/html/6220.html" rel="external">
          "Charcot-Marie-Tooth disease: Genetics, clinical features, and diagnosis", section on 'When to suspect CMT'
         </a>
         ). Genetic testing is key to confirming the diagnosis after electrodiagnostic testing.
        </p>
        <p class="headingAnchor" id="H3146074024">
         <span class="h1">
          MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Management of CMT is currently supportive; however, such supportive therapy can dramatically improve a patient's quality of life. Specific disease-modifying therapy is not available. Optimal management is multidisciplinary, with care provided by neurologists, genetic counselors, nurses, physical and occupational therapists, physiatrists, and orthopedic surgeons [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2469396874">
         <span class="h2">
          Rehabilitation
         </span>
         <span class="headingEndMark">
          —
         </span>
         A comprehensive rehabilitation program plays a crucial role in the management of individuals affected by CMT [
         <a href="#rid1">
          1
         </a>
         ]. All patients should be evaluated for weakness (both distal and proximal), physical conditioning, ambulation, balance, coordination, and manual dexterity. A major goal is the prevention of complications such as joint deformity and falls. Moderate quality evidence suggests progressive resistance exercise programs may improve functional outcomes [
         <a href="#rid2">
          2,3
         </a>
         ]. Daily stretching exercises early in the course of the disease may help delay ankle contractures [
         <a href="#rid3">
          3
         </a>
         ]. Occupational therapy can help to improve function with activities of daily living.
        </p>
        <p>
         Orthotics, including ankle-foot orthoses, are often used to help stabilize the ankles and enhance gait function [
         <a href="#rid4">
          4
         </a>
         ]. Orthopedic foot surgery may be beneficial for severe manifestations of pes cavus deformity and hammer toes, typically during adolescence or early adulthood.
        </p>
        <p>
         However, there are only limited data from high-quality studies to support the utility of rehabilitation interventions for patients with CMT [
         <a href="#rid5">
          5-7
         </a>
         ]. A systematic review published in 2016 identified only seven small randomized controlled trials and four small cohort studies examining physiotherapy or orthotics for patients with CMT [
         <a href="#rid6">
          6
         </a>
         ]. There was evidence that mild to moderate endurance, stretching, and strength training exercises are safe for patients with CMT, can increase arm, pelvic girdle, and knee strength, and can improve performance with activities of daily living. Outcomes for orthotic interventions were mixed, but the one small trial that measured walking ability found that wearing plastic ankle-foot orthoses improved walking control compared with wearing ordinary shoes [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1776745233">
         <span class="h2">
          The role of vitamin supplementation
         </span>
         <span class="headingEndMark">
          —
         </span>
         CMT is not directly associated with vitamin deficiencies, and supplementation has not been proven to be beneficial in traditional forms of CMT. However, patients with CMT who also have vitamin deficiencies that may cause neuropathy should receive appropriate replacement therapy to prevent worsening symptoms. (See
         <a class="local">
          'Concomitant neuropathic conditions'
         </a>
         below.)
        </p>
        <p>
         Some patients with uncommon inherited neuropathies that may mimic CMT can respond to certain types of vitamin supplementation. As examples, Brown-Vialetto-van Laere disease (BVVL) is an autosomal recessive disease that may respond to
         <a class="drug drug_general" data-topicid="9861" href="/z/d/drug information/9861.html" rel="external">
          riboflavin
         </a>
         therapy [
         <a href="#rid9">
          9
         </a>
         ]; a distinct syndrome associated with biallelic pathogenic variants in SLC5A6 may respond to a combination of
         <a class="drug drug_general" data-topicid="120386" href="/z/d/drug information/120386.html" rel="external">
          biotin
         </a>
         ,
         <a class="drug drug_general" data-topicid="10191" href="/z/d/drug information/10191.html" rel="external">
          pantothenic acid
         </a>
         , and lipoic acid [
         <a href="#rid10">
          10
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6220.html" rel="external">
          "Charcot-Marie-Tooth disease: Genetics, clinical features, and diagnosis", section on 'Differential diagnosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3400773135">
         <span class="h2">
          Avoid exacerbating factors
         </span>
        </p>
        <p class="headingAnchor" id="H1921899466">
         <span class="h3">
          Concomitant neuropathic conditions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with CMT may experience further impairments with disorders that cause or exacerbate neuropathy, a list that includes diabetes mellitus, vitamin deficiencies, and immune-mediated neuropathies [
         <a href="#rid1">
          1
         </a>
         ]. Therefore, patients should be screened periodically for these conditions and treated promptly if any are detected. In particular, patients with CMT who experience unusually rapid progression of symptoms should be evaluated for a superimposed immune-mediated or inflammatory neuropathy.
        </p>
        <p class="headingAnchor" id="H503716708">
         <span class="h3">
          Medications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Because patients with CMT have an existing peripheral neuropathy, they are considered to be more susceptible to injury when treated with standard "nontoxic" dosages of neurotoxic agents [
         <a href="#rid11">
          11
         </a>
         ]. A systematic review published in 2006 identified 26 publications, mainly case reports or small case series, describing CMT exacerbation associated with toxic medications, of which 22 involved
         <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">
          vincristine
         </a>
         [
         <a href="#rid12">
          12
         </a>
         ]. Acute worsening or onset of weakness in patients with CMT was observed after vincristine administration of 2 to 4 mg for adults or 1.5 mg/m
         <sup>
          2
         </sup>
         per dose in children. Most of the patients had undiagnosed demyelinating forms of CMT (eg, CMT1A).
        </p>
        <p>
         Thus,
         <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">
          vincristine
         </a>
         is considered to be a definite high-risk medication for patients with CMT, including those who are asymptomatic and/or undiagnosed. Vincristine has long been labeled as contraindicated for patients with demyelinating forms of CMT.
        </p>
        <p>
         Data for other drugs are quite limited, but a list of medications considered to have moderate to significant risk for patients with CMT is as follows [
         <a href="#rid12">
          12
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          Bortezomib
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">
          Cisplatin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">
          carboplatin
         </a>
         ,
         <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">
          oxaliplatin
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">
          Colchicine
         </a>
         (extended use)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">
          Dapsone
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dichloroacetate
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9379" href="/z/d/drug information/9379.html" rel="external">
          Disulfiram
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gold salts
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">
          Leflunomide
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          Metronidazole
         </a>
         /misonidazole (extended use)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">
          Nitrofurantoin
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">
          Nitrous oxide
         </a>
         (inhalation abuse or vitamin B12 deficiency)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Perhexiline (not used in the United States)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pyridoxine (high dose)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9946" href="/z/d/drug information/9946.html" rel="external">
          Stavudine
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10291" href="/z/d/drug information/10291.html" rel="external">
          Suramin
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          Tacrolimus
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Taxol (
         <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">
          paclitaxel
         </a>
         ,
         <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">
          docetaxel
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">
          Thalidomide
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Zalcitabine
        </p>
        <p>
        </p>
        <p>
         A longer list of drugs of concern for patients with CMT, including drugs of uncertain or minor risk and negligible or doubtful risk, can be found online at the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cmtausa.org%2F&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlE9sr0MgX1Qu0gYAeZBOpBuvALUkLBSw0hah5bEtTSir&amp;TOPIC_ID=113945" target="_blank">
          Charcot-Marie-Tooth Association
         </a>
         website.
        </p>
        <p class="headingAnchor" id="H2491206480">
         <span class="h3">
          Uncertain risks with anesthesia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Local anesthesia has been controversial due to theoretical concerns that patients with CMT may have an increased susceptibility to further nerve damage with the use of local anesthetic agents [
         <a href="#rid13">
          13
         </a>
         ]. However, the available limited clinical data suggest otherwise.
        </p>
        <p>
         Regional and general anesthesia have been controversial due to the concern for neuromuscular weakness. A number of small case series and case reports have described uneventful outcomes with regional anesthesia, including both peripheral nerve and neuraxial blocks [
         <a href="#rid14">
          14-16
         </a>
         ]. In individual reports, general anesthesia with
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         and
         <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">
          midazolam
         </a>
         have been used successfully, but prolonged respiratory neuromuscular weakness with
         <a class="drug drug_general" data-topicid="9872" href="/z/d/drug information/9872.html" rel="external">
          rocuronium
         </a>
         has been reported [
         <a href="#rid17">
          17,18
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H814764001">
         <span class="h2">
          Investigational therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Experimental therapies are being tested in both animal models and human participants. This includes neurotropic and symptomatic medications as well as viral vectors to deliver both primary genes and gene-silencing agents. Some such experimental agents include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">
          Progesterone
         </a>
         antagonists may reduce overexpression of
         <em>
          PMP22
         </em>
         and slow disease progression [
         <a href="#rid19">
          19,20
         </a>
         ]. Progesterone can increase
         <em>
          PMP22
         </em>
         expression, and studies in humans have suggested disease exacerbation in pregnancy, a setting in which plasma progesterone increases up to 10-fold [
         <a href="#rid21">
          21
         </a>
         ]. Observations in an animal model were consistent with these findings as the administration of progesterone resulted in a more progressive neuropathy [
         <a href="#rid19">
          19,20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ascorbic acid (
         <a class="drug drug_general" data-topicid="9776" href="/z/d/drug information/9776.html" rel="external">
          vitamin C
         </a>
         ), which is known to promote myelination, appeared promising in an animal model of CMT1A [
         <a href="#rid22">
          22
         </a>
         ]. Ascorbic acid therapy reduced the expression of
         <em>
          PMP22
         </em>
         to a level below that required to induce the disease. This change was associated with remyelination, amelioration of the CMT1A phenotype, and prolonged lifespan. However, there was no clear benefit of ascorbic acid in a 12-month randomized controlled trial of 81 children with CMT1A [
         <a href="#rid23">
          23
         </a>
         ], in a similar trial of 179 adults with CMT1A [
         <a href="#rid24">
          24
         </a>
         ], or in a smaller trial of 11 patients younger than age 25 years [
         <a href="#rid25">
          25
         </a>
         ]. Since disease progression in CMT1A is typically slow, trials with longer treatment periods may be necessary to detect any benefit [
         <a href="#rid26">
          26,27
         </a>
         ]. However, it is discouraging that any potential benefit would be that modest.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Neurotrophin-3 (NT3) improved axonal regeneration and associated myelination in both a xenograft model of Schwann cells with a
         <em>
          PMP22
         </em>
         duplication and in a mouse model with a pathogenic
         <em>
          PMP22
         </em>
         single-nucleotide variant (SNV) [
         <a href="#rid28">
          28
         </a>
         ]. In the same report, a single-blinded pilot clinical trial involving eight patients with CMT1A found that NT3 treatment for six months was associated with improved sural nerve myelinated fiber regeneration compared with placebo treatment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          GARS
         </em>
         has been the target of several preclinical studies. A study testing intramuscular AAV-mediated gene transfer of
         <em>
          NT-3
         </em>
         into mice with pathogenic variants in
         <em>
          GARS
         </em>
         (modeling CMT2D) showed functional and electrophysiologic improvements [
         <a href="#rid29">
          29
         </a>
         ]. AAV-mediated delivery of RNAi sequences targeting variant
         <em>
          GARS
         </em>
         mRNA into mouse models of CMT2D showed therapeutic effects, especially when treatment was administered at birth [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Curcumin has been studied in a mouse model of CMT1A and led to rejuvenation of myelinated axons in this model [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A compound oral agent consisting of
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         ,
         <a class="drug drug_general" data-topicid="9679" href="/z/d/drug information/9679.html" rel="external">
          naltrexone
         </a>
         , and D-sorbitol (PXT3003) in individuals with CMT1A showed benefit in the Overall Neuropathy Limitations Scale in a small clinical trial [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          MFN2
         </em>
         agonists have been found to improve mitochondrial defects in a mouse model of CMT2A [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Antisense oligonucleotide suppression of
         <em>
          PMP22
         </em>
         mRNA levels in a model of CMT1A [
         <a href="#rid34">
          34
         </a>
         ] – A molecular approach for CMT1A is to silence the excess expression of
         <em>
          PMP22
         </em>
         . A study in a rat model of CMT1A showed improvement on functional and myelination measures after intraneural delivery of AAV2/9 carrying shRNAs targeting
         <em>
          PMP22
         </em>
         mRNA [
         <a href="#rid35">
          35
         </a>
         ]. In transgenic mouse models of CMT1A, administration of siRNA targeting PMP22 resulted in functional and histopathological improvement [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intrathecal gene therapy was studied in mouse models of CMTX1 replicating several different variants of
         <em>
          GJB1
         </em>
         , and the response varied significantly based on the specific variants represented [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Direct gene replacement is a promising strategy for multiple forms of CMT [
         <a href="#rid34">
          34
         </a>
         ]. A mouse model of CMT4J was dosed with AAV9 containing FIG4, showing good motor function, neurophysiologic outcomes, and histopathological findings [
         <a href="#rid38">
          38
         </a>
         ]. Intrathecal injection of AAV9 carrying
         <em>
          GJB1/Cx32
         </em>
         into Gjb1-null mice led to improved motor function and electrophysiologic parameters [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         One study using a CRISPR/Cas9 approach in a mouse model of CMT1A showed that TATA-box targeting of PMP22 led to downregulation of PMP22 expression and preservation of myelin and axons [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Axonal neuregulin 1 type III (Nrg1TIII) promotes myelination via specific pathways including PI3K/Akt and MAPK/Erk. Genetic overexpression of Nrg1TIII was shown to improve neurophysiological and morphological parameters in a mouse model of CMT1B [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3402001722">
         <span class="h2">
          Pregnant patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         The management of pregnant patients with CMT is similar to that of pregnant patients without CMT. CMT by itself is not an indication for cesarean delivery, which should be reserved for the usual obstetric indications only. However, pregnant patients with CMT should be monitored for complications during labor and delivery.
        </p>
        <p>
         An observational study of 193 pregnancies in 86 patients with CMT showed increased rates of placenta previa, abnormal presentations, and preterm deliveries, but not postpartum bleeding [
         <a href="#rid42">
          42
         </a>
         ]. It is not clear whether the increased frequency of malpresentation was related to early symptoms in affected fetuses because the disorder typically does not present until later in childhood. CMT status worsened in nearly 10 percent of the pregnancies during gestation, with no recovery in most of those patients in this study. Other studies have similarly found elevated rates of abnormal fetal presentations in patients with CMT but also reported higher rates of postpartum bleeding than the general obstetric population [
         <a href="#rid43">
          43
         </a>
         ]. One possible explanation for this finding is atony related to the effect of the disease on uterine adrenergic nerves. Birth weights were comparable to those in unaffected pregnancies.
        </p>
        <p class="headingAnchor" id="H62077884">
         <span class="h2">
          Outcome measures
         </span>
         <span class="headingEndMark">
          —
         </span>
         Outcome measures are more relevant to clinical trials than to routine clinical care, but with the surge in investigational therapies and the growing interest in human clinical trials for CMT, it is important to establish commonly used outcome measures. For adults, a multi-item CMT Functional Outcome Measure (CMT-FOM) was validated [
         <a href="#rid44">
          44
         </a>
         ], and other single-item and multi-item outcome measures have been studied [
         <a href="#rid45">
          45
         </a>
         ]. Outcome measures have been proposed specifically for infants with CMT [
         <a href="#rid46">
          46
         </a>
         ], including an alternate multi-item scale that was validated for this age group [
         <a href="#rid47">
          47
         </a>
         ]. Electrophysiologic outcome measures could also potentially track progression and monitor for treatment effects. In addition to standard electrophysiologic measures, more advanced techniques such as motor unit number index (see
         <a class="medical medical_review" href="/z/d/html/5142.html" rel="external">
          "Overview of nerve conduction studies", section on 'Motor unit number estimates (MUNE)'
         </a>
         ) may be considered for such purposes [
         <a href="#rid48">
          48
         </a>
         ]. Imaging modalities such as magnetic resonance imaging (MRI) are being adopted for use as outcome measures and for monitoring of clinical progression in neuromuscular diseases, including CMT [
         <a href="#rid49">
          49
         </a>
         ]. It is expected that these outcome measures will become increasingly used in clinical trials, and some of the individual measures may be useful for tracking disease progression during routine clinical care.
        </p>
        <p class="headingAnchor" id="H1107688648">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         CMT in most cases is characterized by onset in the first or second decade of life with very slow progression [
         <a href="#rid50">
          50
         </a>
         ]. Disability generally increases with age, but there is considerable variability in age of onset, rate of progression, and clinical severity both between and within different CMT subtypes. Functional outcomes vary from minor impairments to severe lower limb atrophy and wheelchair dependence. Nevertheless, many patients retain at least partial ambulatory abilities for all or most of their lives, and it is rare for CMT to shorten life expectancy.
        </p>
        <p>
         With CMT1A, the most common subtype, progression often results in gait difficulty, but complete loss of ambulation is uncommon, and life expectance is normal. (See
         <a class="medical medical_review" href="/z/d/html/6220.html" rel="external">
          "Charcot-Marie-Tooth disease: Genetics, clinical features, and diagnosis", section on 'CMT1'
         </a>
         .)
        </p>
        <p>
         With CMTX1, the second most common CMT subtype, disease progression to severe disability occurs on average by the fifth decade in males [
         <a href="#rid51">
          51
         </a>
         ], but lifespan is not shortened [
         <a href="#rid52">
          52
         </a>
         ]. Females with CMTX1 tend to have milder clinical courses. (See
         <a class="medical medical_review" href="/z/d/html/6220.html" rel="external">
          "Charcot-Marie-Tooth disease: Genetics, clinical features, and diagnosis", section on 'CMTX1'
         </a>
         .)
        </p>
        <p>
         Respiratory failure due to neuromuscular weakness of the diaphragm or vocal cords is a rare complication of CMT but has been reported in a number of subtypes of CMT, including CMT1A [
         <a href="#rid50">
          50,53
         </a>
         ].
        </p>
        <p>
         CMT has a major impact on the quality of life of affected individuals. A 2019 study from Germany of 397 patients with genetically confirmed diagnoses of CMT estimated that the total annual cost of illness per patient was USD $22,362 [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3172662540">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/83812.html" rel="external">
          "Patient education: Charcot-Marie-Tooth disease (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4203951449">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         – Specific therapy for Charcot-Marie-Tooth disease (CMT) is not yet available. Optimal management is multidisciplinary. (See
         <a class="local">
          'Management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A comprehensive rehabilitation program plays a crucial role in the management of individuals affected by CMT. Stretching, endurance, and strengthening exercises and orthotics may help to improve function. (See
         <a class="local">
          'Rehabilitation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with CMT should be screened periodically for conditions that cause or exacerbate neuropathy, such as diabetes mellitus, vitamin deficiencies, and superimposed immune-mediated neuropathies. (See
         <a class="local">
          'Concomitant neuropathic conditions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with CMT should avoid drugs that can exacerbate neuropathy, particularly
         <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">
          vincristine
         </a>
         . (See
         <a class="local">
          'Medications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – CMT in most cases is characterized by onset in the first or second decade of life with very slow progression. Disability generally increases with age. However, there is considerable variability in age of onset, rate of progression, and clinical severity, both between and within different CMT subtypes. (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Saporta MA. Charcot-Marie-Tooth disease and other inherited neuropathies. Continuum (Minneap Minn) 2014; 20:1208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burns J, Sman AD, Cornett KMD, et al. Safety and efficacy of progressive resistance exercise for Charcot-Marie-Tooth disease in children: a randomised, double-blind, sham-controlled trial. Lancet Child Adolesc Health 2017; 1:106.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yiu EM, Bray P, Baets J, et al. Clinical practice guideline for the management of paediatric Charcot-Marie-Tooth disease. J Neurol Neurosurg Psychiatry 2022; 93:530.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Õunpuu S, Garibay E, Acsadi G, et al. The impact of orthoses on gait in children with Charcot-Marie-Tooth disease. Gait Posture 2021; 85:198.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Young P, De Jonghe P, Stögbauer F, Butterfass-Bahloul T. Treatment for Charcot-Marie-Tooth disease. Cochrane Database Syst Rev 2008; :CD006052.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corrado B, Ciardi G, Bargigli C. Rehabilitation Management of the Charcot-Marie-Tooth Syndrome: A Systematic Review of the Literature. Medicine (Baltimore) 2016; 95:e3278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sman AD, Hackett D, Fiatarone Singh M, et al. Systematic review of exercise for Charcot-Marie-Tooth disease. J Peripher Nerv Syst 2015; 20:347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guillebastre B, Calmels P, Rougier PR. Assessment of appropriate ankle-foot orthoses models for patients with Charcot-Marie-Tooth disease. Am J Phys Med Rehabil 2011; 90:619.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Green P, Wiseman M, Crow YJ, et al. Brown-Vialetto-Van Laere syndrome, a ponto-bulbar palsy with deafness, is caused by mutations in c20orf54. Am J Hum Genet 2010; 86:485.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holling T, Nampoothiri S, Tarhan B, et al. Novel biallelic variants expand the SLC5A6-related phenotypic spectrum. Eur J Hum Genet 2022; 30:439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chaudhry V, Chaudhry M, Crawford TO, et al. Toxic neuropathy in patients with pre-existing neuropathy. Neurology 2003; 60:337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weimer LH, Podwall D. Medication-induced exacerbation of neuropathy in Charcot Marie Tooth disease. J Neurol Sci 2006; 242:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guay J. First, do no harm: balancing the risks and benefits of regional anesthesia in patients with underlying neurological disease. Can J Anaesth 2008; 55:489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greenwood JJ, Scott WE. Charcot-Marie-Tooth disease: peripartum management of two contrasting clinical cases. Int J Obstet Anesth 2007; 16:149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dhir S, Balasubramanian S, Ross D. Ultrasound-guided peripheral regional blockade in patients with Charcot-Marie-Tooth disease: a review of three cases. Can J Anaesth 2008; 55:515.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brock M, Guinn C, Jones M. Anesthetic management of an obstetric patient with Charcot-Marie-Tooth disease: a case study. AANA J 2009; 77:335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ohshita N, Oka S, Tsuji K, et al. Anesthetic Management of a Patient With Charcot-Marie-Tooth Disease. Anesth Prog 2016; 63:80.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hiramatsu S, Moriwaki K, Nakao M, Tsutsumi YM. Rocuronium-induced respiratory paralysis refractory to sugammadex in Charcot-Marie-Tooth disease. Can J Anaesth 2022; 69:364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sereda MW, Meyer zu Hörste G, Suter U, et al. Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A). Nat Med 2003; 9:1533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meyer zu Horste G, Prukop T, Liebetanz D, et al. Antiprogesterone therapy uncouples axonal loss from demyelination in a transgenic rat model of CMT1A neuropathy. Ann Neurol 2007; 61:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rudnik-Schöneborn S, Röhrig D, Nicholson G, Zerres K. Pregnancy and delivery in Charcot-Marie-Tooth disease type 1. Neurology 1993; 43:2011.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Passage E, Norreel JC, Noack-Fraissignes P, et al. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med 2004; 10:396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burns J, Ouvrier RA, Yiu EM, et al. Ascorbic acid for Charcot-Marie-Tooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trial. Lancet Neurol 2009; 8:537.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Micallef J, Attarian S, Dubourg O, et al. Effect of ascorbic acid in patients with Charcot-Marie-Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2009; 8:1103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verhamme C, de Haan RJ, Vermeulen M, et al. Oral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double-blind, placebo-controlled phase II trial. BMC Med 2009; 7:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pareyson D, Solari A. Charcot-Marie-Tooth disease type 1A: is ascorbic acid effective? Lancet Neurol 2009; 8:1075.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gess B, Baets J, De Jonghe P, et al. Ascorbic acid for the treatment of Charcot-Marie-Tooth disease. Cochrane Database Syst Rev 2015; :CD011952.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sahenk Z, Nagaraja HN, McCracken BS, et al. NT-3 promotes nerve regeneration and sensory improvement in CMT1A mouse models and in patients. Neurology 2005; 65:681.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ozes B, Moss K, Myers M, et al. AAV1.NT-3 gene therapy in a CMT2D model: phenotypic improvements in GarsP278KY/+ mice. Brain Commun 2021; 3:fcab252.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morelli KH, Griffin LB, Pyne NK, et al. Allele-specific RNA interference prevents neuropathy in Charcot-Marie-Tooth disease type 2D mouse models. J Clin Invest 2019; 129:5568.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khajavi M, Shiga K, Wiszniewski W, et al. Oral curcumin mitigates the clinical and neuropathologic phenotype of the Trembler-J mouse: a potential therapy for inherited neuropathy. Am J Hum Genet 2007; 81:438.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Attarian S, Young P, Brannagan TH, et al. A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot-Marie-Tooth type 1A. Orphanet J Rare Dis 2021; 16:433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rocha AG, Franco A, Krezel AM, et al. MFN2 agonists reverse mitochondrial defects in preclinical models of Charcot-Marie-Tooth disease type 2A. Science 2018; 360:336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morena J, Gupta A, Hoyle JC. Charcot-Marie-Tooth: From Molecules to Therapy. Int J Mol Sci 2019; 20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gautier B, Hajjar H, Soares S, et al. AAV2/9-mediated silencing of PMP22 prevents the development of pathological features in a rat model of Charcot-Marie-Tooth disease 1 A. Nat Commun 2021; 12:2356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boutary S, Caillaud M, El Madani M, et al. Squalenoyl siRNA PMP22 nanoparticles are effective in treating mouse models of Charcot-Marie-Tooth disease type 1 A. Commun Biol 2021; 4:317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kagiava A, Karaiskos C, Richter J, et al. Intrathecal gene therapy in mouse models expressing CMT1X mutations. Hum Mol Genet 2018; 27:1460.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Presa M, Bailey RM, Davis C, et al. AAV9-mediated FIG4 delivery prolongs life span in Charcot-Marie-Tooth disease type 4J mouse model. J Clin Invest 2021; 131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kagiava A, Karaiskos C, Richter J, et al. AAV9-mediated Schwann cell-targeted gene therapy rescues a model of demyelinating neuropathy. Gene Ther 2021; 28:659.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee JS, Lee JY, Song DW, et al. Targeted PMP22 TATA-box editing by CRISPR/Cas9 reduces demyelinating neuropathy of Charcot-Marie-Tooth disease type 1A in mice. Nucleic Acids Res 2020; 48:130.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scapin C, Ferri C, Pettinato E, et al. Enhanced axonal neuregulin-1 type-III signaling ameliorates neurophysiology and hypomyelination in a Charcot-Marie-Tooth type 1B mouse model. Hum Mol Genet 2019; 28:992.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pisciotta C, Calabrese D, Santoro L, et al. Pregnancy in Charcot-Marie-Tooth disease: Data from the Italian CMT national registry. Neurology 2020; 95:e3180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoff JM, Gilhus NE, Daltveit AK. Pregnancies and deliveries in patients with Charcot-Marie-Tooth disease. Neurology 2005; 64:459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eichinger K, Burns J, Cornett K, et al. The Charcot-Marie-Tooth Functional Outcome Measure (CMT-FOM). Neurology 2018; 91:e1381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mori L, Prada V, Signori A, et al. Outcome measures in the clinical evaluation of ambulatory Charcot-Marie-Tooth 1A subjects. Eur J Phys Rehabil Med 2019; 55:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mandarakas MR, Rose KJ, Sanmaneechai O, et al. Functional outcome measures for infantile Charcot-Marie-Tooth disease: a systematic review. J Peripher Nerv Syst 2018; 23:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mandarakas MR, Menezes MP, Rose KJ, et al. Development and validation of the Charcot-Marie-Tooth Disease Infant Scale. Brain 2018; 141:3319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bas J, Delmont E, Fatehi F, et al. Motor unit number index correlates with disability in Charcot-Marie-Tooth disease. Clin Neurophysiol 2018; 129:1390.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cornett KMD, Wojciechowski E, Sman AD, et al. Magnetic resonance imaging of the anterior compartment of the lower leg is a biomarker for weakness, disability, and impaired gait in childhood Charcot-Marie-Tooth disease. Muscle Nerve 2019; 59:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pareyson D, Marchesi C. Diagnosis, natural history, and management of Charcot-Marie-Tooth disease. Lancet Neurol 2009; 8:654.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shy ME, Siskind C, Swan ER, et al. CMT1X phenotypes represent loss of GJB1 gene function. Neurology 2007; 68:849.
          </a>
         </li>
         <li class="breakAll">
          Bird TD. Charcot-Marie-Tooth neuropathy X type 1. GeneReviews. https://www.ncbi.nlm.nih.gov/books/NBK1374/ (Accessed on July 14, 2017).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Werheid F, Azzedine H, Zwerenz E, et al. Underestimated associated features in CMT neuropathies: clinical indicators for the causative gene? Brain Behav 2016; 6:e00451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schorling E, Thiele S, Gumbert L, et al. Cost of illness in Charcot-Marie-Tooth neuropathy: Results from Germany. Neurology 2019; 92:e2027.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 113945 Version 10.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25299278" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Charcot-Marie-Tooth disease and other inherited neuropathies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30169201" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Safety and efficacy of progressive resistance exercise for Charcot-Marie-Tooth disease in children: a randomised, double-blind, sham-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35140138" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Clinical practice guideline for the management of paediatric Charcot-Marie-Tooth disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33610823" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : The impact of orthoses on gait in children with Charcot-Marie-Tooth disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18254090" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Treatment for Charcot-Marie-Tooth disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27124017" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Rehabilitation Management of the Charcot-Marie-Tooth Syndrome: A Systematic Review of the Literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26010435" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Systematic review of exercise for Charcot-Marie-Tooth disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21681059" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Assessment of appropriate ankle-foot orthoses models for patients with Charcot-Marie-Tooth disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20206331" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Brown-Vialetto-Van Laere syndrome, a ponto-bulbar palsy with deafness, is caused by mutations in c20orf54.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35013551" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Novel biallelic variants expand the SLC5A6-related phenotypic spectrum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12552058" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Toxic neuropathy in patients with pre-existing neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16386273" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Medication-induced exacerbation of neuropathy in Charcot Marie Tooth disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18676382" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : First, do no harm: balancing the risks and benefits of regional anesthesia in patients with underlying neurological disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17275278" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Charcot-Marie-Tooth disease: peripartum management of two contrasting clinical cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18676386" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Ultrasound-guided peripheral regional blockade in patients with Charcot-Marie-Tooth disease: a review of three cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19911641" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Anesthetic management of an obstetric patient with Charcot-Marie-Tooth disease: a case study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27269665" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Anesthetic Management of a Patient With Charcot-Marie-Tooth Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34902106" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Rocuronium-induced respiratory paralysis refractory to sugammadex in Charcot-Marie-Tooth disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14608378" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17262851" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Antiprogesterone therapy uncouples axonal loss from demyelination in a transgenic rat model of CMT1A neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8413959" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Pregnancy and delivery in Charcot-Marie-Tooth disease type 1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15034573" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19427269" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Ascorbic acid for Charcot-Marie-Tooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19818690" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Effect of ascorbic acid in patients with Charcot-Marie-Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19909499" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Oral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double-blind, placebo-controlled phase II trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19818689" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Charcot-Marie-Tooth disease type 1A: is ascorbic acid effective?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26662471" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Ascorbic acid for the treatment of Charcot-Marie-Tooth disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16157899" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : NT-3 promotes nerve regeneration and sensory improvement in CMT1A mouse models and in patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34755111" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : AAV1.NT-3 gene therapy in a CMT2D model: phenotypic improvements in GarsP278KY/+ mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31557132" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Allele-specific RNA interference prevents neuropathy in Charcot-Marie-Tooth disease type 2D mouse models.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17701891" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Oral curcumin mitigates the clinical and neuropathologic phenotype of the Trembler-J mouse: a potential therapy for inherited neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34656144" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot-Marie-Tooth type 1A.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29674596" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : MFN2 agonists reverse mitochondrial defects in preclinical models of Charcot-Marie-Tooth disease type 2A.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31336816" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Charcot-Marie-Tooth: From Molecules to Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33883545" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : AAV2/9-mediated silencing of PMP22 prevents the development of pathological features in a rat model of Charcot-Marie-Tooth disease 1 A.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33750896" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Squalenoyl siRNA PMP22 nanoparticles are effective in treating mouse models of Charcot-Marie-Tooth disease type 1 A.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29462293" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Intrathecal gene therapy in mouse models expressing CMT1X mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33878035" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : AAV9-mediated FIG4 delivery prolongs life span in Charcot-Marie-Tooth disease type 4J mouse model.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33692503" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : AAV9-mediated Schwann cell-targeted gene therapy rescues a model of demyelinating neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31713617" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Targeted PMP22 TATA-box editing by CRISPR/Cas9 reduces demyelinating neuropathy of Charcot-Marie-Tooth disease type 1A in mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30481294" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Enhanced axonal neuregulin-1 type-III signaling ameliorates neurophysiology and hypomyelination in a Charcot-Marie-Tooth type 1B mouse model.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32928981" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Pregnancy in Charcot-Marie-Tooth disease: Data from the Italian CMT national registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15699375" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Pregnancies and deliveries in patients with Charcot-Marie-Tooth disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30232254" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : The Charcot-Marie-Tooth Functional Outcome Measure (CMT-FOM).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29898585" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Outcome measures in the clinical evaluation of ambulatory Charcot-Marie-Tooth 1A subjects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29521025" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Functional outcome measures for infantile Charcot-Marie-Tooth disease: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30476010" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Development and validation of the Charcot-Marie-Tooth Disease Infant Scale.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29729594" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Motor unit number index correlates with disability in Charcot-Marie-Tooth disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30265406" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Magnetic resonance imaging of the anterior compartment of the lower leg is a biomarker for weakness, disability, and impaired gait in childhood Charcot-Marie-Tooth disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19539237" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Diagnosis, natural history, and management of Charcot-Marie-Tooth disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17353473" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : CMT1X phenotypes represent loss of GJB1 gene function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17353473" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : CMT1X phenotypes represent loss of GJB1 gene function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27088055" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Underestimated associated features in CMT neuropathies: clinical indicators for the causative gene?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30918088" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Cost of illness in Charcot-Marie-Tooth neuropathy: Results from Germany.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
